Not for the 'Faint of Heart' | GenomeWeb

Diagnostics are a tough business, writes life sciences venture capitalist Bruce Booth.

And he should know — he's currently in the process of unwinding cancer diagnostics company On-Q-Ity, an investment by his firm, Atlas Ventures, that didn't quite work out.

The reading public is the beneficiary of Booth's loss, though, as he performs a post-mortem of sorts, looking at what went wrong.

Among the lessons learned:

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Change Afoot

Such High Hopes

Words to Dollars

To Regulate or Not?

In PLOS this week: founder mutation linked to some leukoencephalopathy cases, transcript and protein profiles of the kissing bug, and more.

BGI CEO Ye Yin says that mapping variation within the human genome will bring a "big data revolution" to healthcare, Wired UK writes.

All the images that investigators produce through their research present a challenge to share, Nature News reports.

The House of Representatives science committee has approved a measure that includes new rules for large National Science Foundation projects, ScienceInsider reports.